Connection

JORGE E CORTES to Immunotoxins

This is a "connection" page, showing publications JORGE E CORTES has written about Immunotoxins.
Connection Strength

0.530
  1. Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies. Haematologica. 2013 Feb; 98(2):217-21.
    View in: PubMed
    Score: 0.401
  2. Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions. Ann Pharmacother. 2003 Sep; 37(9):1182-5.
    View in: PubMed
    Score: 0.054
  3. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood. 2002 Jun 15; 99(12):4343-9.
    View in: PubMed
    Score: 0.050
  4. Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy. Haematologica. 2002 Oct; 87(10):1114-6.
    View in: PubMed
    Score: 0.013
  5. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002 Oct; 118(4):560-6.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.